Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIFANG: Tezepelumab in adults with chronic rhinosinusitis with nasal polyps in China
CTR20260829Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by AstraZeneca. Started Jun 2026; status: active.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20260829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260829.